Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NU E Power Corp. Announces Closing of Non-Brokered Private Placement for $1.7 Million. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Tyra Biosciences Inc TYRA

Healthcare Biotechnology
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions... see more

Recent & Breaking News (NDAQ:TYRA)

Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer

PR Newswire December 1, 2025

Tyra Biosciences Announces Participation at Upcoming Investor Events

PR Newswire November 12, 2025

Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights

PR Newswire November 5, 2025

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

PR Newswire August 21, 2025

Tyra Biosciences Announces Participation at Upcoming Investor Events

PR Newswire August 20, 2025

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

PR Newswire August 14, 2025

Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series

PR Newswire July 21, 2025

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

PR Newswire July 8, 2025

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

PR Newswire June 30, 2025

Tyra Biosciences to Participate at Upcoming Investor Conferences

PR Newswire May 12, 2025

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

PR Newswire May 8, 2025

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

PR Newswire March 27, 2025

Tyra Biosciences to Present at Upcoming Investor Conferences

PR Newswire February 11, 2025

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

PR Newswire January 29, 2025

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

PR Newswire January 22, 2025

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

PR Newswire January 10, 2025

Tyra Biosciences to Present at Upcoming Investor Conferences

PR Newswire November 13, 2024

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

PR Newswire November 7, 2024

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

PR Newswire October 28, 2024

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

PR Newswire October 24, 2024

Podcasts